07.11.2016 21:52:00
|
21st Century Oncology, Inc -- Moody's says 21st Century's Missed Interest Payment is a Credit Negative; Ratings Unaffected
New York, November 07, 2016 -- Moody's Investors Service ("Moody's") said that 21st Century Oncology, Inc's ("21st Century") failure to make the semi-annual interest payment under its senior notes due 2023 is a credit negative. The company is within the 30 day cure period, which ends December 1, 2016. However, the missed interest payment does not currently affect 21st Century's Caa3 Corporate Family Rating or negative outlook as they already incorporate high default risk. For further information please see the Issuer Comment at www.moodys.com.